- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Masking.
Displaying page 1 of 1.
EudraCT Number: 2006-006545-13 | Sponsor Protocol Number: LX211-03-UV | Start Date*: 2007-04-27 | |||||||||||
Sponsor Name:Lux Biosciences GmbH | |||||||||||||
Full Title: A Double-Masked, Placebo-Controlled, Multi-Centre, Dose-Ranging Study to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight Threatening, Non-Infectious Uveitis. | |||||||||||||
Medical condition: Subjects with active sight-threatening, non-infectious anterior, anterior and intermediate- or panuveitis who require systemic immunosuppression for the control of their disease. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006543-31 | Sponsor Protocol Number: LX211-01-UV | Start Date*: 2007-04-13 | |||||||||||
Sponsor Name:Lux Biosciences GmbH | |||||||||||||
Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight ... | |||||||||||||
Medical condition: Subjects with active sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003106-72 | Sponsor Protocol Number: IIBSP-SUR-2022-61 | Start Date*: 2023-05-26 |
Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau | ||
Full Title: Single-blind randomized clinical trial in premature infants with Respiratory Distress Syndrome (RDS) amenable to treatment with exogenous surfactant identified early by pulmonary ultrasonography | ||
Medical condition: Respiratory Distress Syndrome | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-005178-10 | Sponsor Protocol Number: AM-101-CL-08-01 | Start Date*: 2009-01-27 | |||||||||||
Sponsor Name:Auris Medical AG | |||||||||||||
Full Title: Efficacy of AM 101 in Patients with Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II Study | |||||||||||||
Medical condition: Acute inner ear tinnitus following acute acoustic trauma, sudden deafness, or acute otitis media. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004697-28 | Sponsor Protocol Number: 523001.01.099 | Start Date*: 2012-06-01 | |||||||||||
Sponsor Name:Dr. W. Schwabe GmbH & Co. KG | |||||||||||||
Full Title: Randomised, double-blind trial to compare the treatment effects of Ginkgo biloba extract EGb 761® and pentoxifylline in patients with sub-chronic and chronic tinnitus focussing on psycho-social pro... | |||||||||||||
Medical condition: chronic or sub-chronic tinnitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006544-66 | Sponsor Protocol Number: LX211-02-UV | Start Date*: 2007-04-13 | |||||||||||
Sponsor Name:Lux Biosciences GmbH | |||||||||||||
Full Title: A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Centre, Dose-Ranging Study with an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Qu... | |||||||||||||
Medical condition: Subjects with clinically quiescent sight-threatening, non-infectious intermediate-, anterior and intermediate-, posterior- or pan-uveitis requiring systemic immune suppression. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) GB (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022166-27 | Sponsor Protocol Number: CBGG492A2210 | Start Date*: 2010-11-29 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo- controlled, cross-over, proof of concept study comparing the effects of both single dose and repeated dosing treatment for 2 weeks of BGG492 in p... | |||||||||||||
Medical condition: indication “tinnitus”. condition: patients with chronic subjective tinnitus. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005384-24 | Sponsor Protocol Number: AM-101-CL-10-02 | Start Date*: 2012-02-06 | |||||||||||
Sponsor Name:Auris Medical AG | |||||||||||||
Full Title: TACTT1 | |||||||||||||
Medical condition: Acute inner ear tinnitus following acute acustic trauma, acute otitis media, middle ear surgery, or inner ear barotrauma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000395-15 | Sponsor Protocol Number: MATR1001 | Start Date*: 2016-03-10 | |||||||||||
Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust | |||||||||||||
Full Title: The use of bevacizumab as a modulator of wound healing following trabeculectomy surgery: A Single Centre Randomised Controlled Phase III Pilot Study. | |||||||||||||
Medical condition: Primary Open Angle Glaucoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023915-33 | Sponsor Protocol Number: PXL008-004 | Start Date*: 2011-05-30 | |||||||||||
Sponsor Name:POXEL S.A. | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, parallel-group study of the safety and efficacy of imeglimin or placebo add-on therapy in type 2 diabetic subjects not adequately controlled by sitagli... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) LV (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023483-41 | Sponsor Protocol Number: I10E-0718 | Start Date*: 2011-03-01 | |||||||||||||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||||||||||||
Full Title: A MULTICENTER STUDY ON THE EFFICACY, SAFETY AND PHARMACOKINETICS OF I10E IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID) | |||||||||||||||||||||||
Medical condition: a primary immunodeficiency as defined by the ESID and validated by a reference centre : • X-linked agammaglobulinemia (XLA) • Common variable immunodeficiency (CVID) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Completed) FR (Completed) Outside EU/EEA | |||||||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2015-002409-13 | Sponsor Protocol Number: AL1501AV | Start Date*: 2015-11-19 | |||||||||||||||||||||||||||||||
Sponsor Name:Allergopharma GmbH & Co. KG | |||||||||||||||||||||||||||||||||
Full Title: A multicenter, randomized, open-label clinical trial to evaluate safety and tolerability of a year-round initiation of specific immunotherapy with an aluminum hydroxide adsorbed allergoid preparati... | |||||||||||||||||||||||||||||||||
Medical condition: Patients with moderate to severe seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma. | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-001354-29 | Sponsor Protocol Number: I10E-0719 | Start Date*: 2011-10-12 | |||||||||||
Sponsor Name:LFB BIOTECHNOLOGIES | |||||||||||||
Full Title: An open-label, multicentre efficacy and safety study of I10E in patients with primary Immune ThrombocytoPenia (ITP) | |||||||||||||
Medical condition: ITP diagnosis being defined by ASH-2011 and BCSH 2010 criteria adopting the new consensus terminology proposed by an international working group (Rodeghiero et al, 2009) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: Removed from public view |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
